

Supplemental Table 1. Relative Risk* of Transverse Myelitis in the 2-42 day risk interval following vaccines, compared to remainder of the 9 months post vaccination, Vaccine Safety Datalink (VSD) 2007-2013.

Vaccine Type†	Vaccinated cases		Comparison Risk Sets: Cases and Non-cases**		Adjusted Odds Ratio	95% CI	P-value
	N	% In Exposure Interval	N	% In Exposure Interval			
MMR	1	0	191	19.9	0	(0.0,76.5)	0.8
DTaP/IPV/ HBV	1	0	153	56.2	0	(0.0,14.8)	0.44
MCV4 Sanofi	3	33.3	10,332	14.7	2.4	(0.1,33.5)	0.54
Tdap	16	6.3	123,404	15.3	0.4	(0.0,2.0)	0.33
RV5	1	0	152	55.3	0	(0.0,15.4)	0.45
Zoster	2	50	6,115	17.1	4.4	(0.1,172.2)	0.37
PNCV13	1	0	157	58	0	(0.0,13.8)	0.42
VZV	4	0	4,796	15.4	0	(0.0,5.5)	0.47
PPSV23	5	0	28,218	13.4	0	(0.0,5.2)	0.48
HPV4	3	0	7,404	17.3	0	(0.0,8.1)	0.56
Any MCV4	3	33.3	10,332	14.7	2.4	(0.1,33.5)	0.54
Any PNCV	2	0	221	48.4	0	(0.0,4.8)	0.32
HAV	4	0	3,107	17	0	(0.0,6.9)	0.54
HBV	2	0	286	18.5	0	(0.0,16.7)	0.68
Hib	1	0	160	57.5	0	(0.0,14.0)	0.43
IIV	39	20.5	977,004	12.6	2.9	(0.8,9.4)	0.09
LAIV	2	50	3,887	41.7	7.3	(0.0,1423.7)	0.59
Td	2	0	3,458	11.6	0	(0.0,22.1)	0.74
Any	67	17.9	1,722,639	17.7	1.1	(0.5,2.1)	0.87

*This relative risk is estimated by the odds ratio, using the case centered method, as described in Methods.

** Comparison Risk Sets: Cases and Non-cases: All VSD members similar to cases (matched on age, sex, vaccine type and VSD site) on the onset date of the case. N represents the number of people in all the risk sets.

† Vaccine abbreviations are clarified in Table 1 in the publication.

ne: not evaluable; CI: confidence interval

Supplemental Table 2. Relative Risk* of Acute Disseminated Encephalomyelitis in the 2-42 day risk interval following vaccines, compared to remainder of the 9 months post vaccination, Kaiser Permanente Northern California 2007-2013.

Vaccine Type	Cases		Comparison Risk Sets: Cases + Non-cases**		Adjusted Odds Ratio	95% CI	P-value
	N	% In Exposure Interval	N	% In Exposure Interval			
MMR	6	33.3	47,274	18.4	2.4	(0.3,14.7)	0.36
IPV	1	0	6,077	12.5	0	(0.0,132.5)	0.87
PNCV7	3	0	40,214	9.1	0	(0.0,22.2)	0.75
MCV4San	3	0	14,951	17	0	(0.0,8.9)	0.58
Tdap	3	66.7	10,176	19.6	9.2	(0.7,276.3)	0.09
RV5	1	0	4,334	0	0	(0.0,82326.4)	1
DTaP/IPV/ Hib	2	0	5,458	14	0	(0.0,21.4)	0.74
Zoster	1	0	3,247	17	0	(0.0,92.6)	0.83
DTaP/IP	4	25	30,160	16.7	2	(0.1,20.8)	0.59
PNCV13	3	33.3	7,275	38.5	1.6	(0.0,47.3)	0.82
DTaP	1	0	6,206	12.6	0	(0.0,131.2)	0.87
VZV	6	33.3	45,758	19	2.1	(0.3,12.7)	0.42
MPSV4	1	100	3	33.3	ne	(0.1, -)	0.33
PPSV23	3	0	13,539	18	0	(0.0,7.3)	0.53
HPV4	6	16.7	57,938	21.6	0.7	(0.0,5.4)	0.85
MMR-V	1	0	2,049	12.2	0	(0.0,136.1)	0.88
Any MCV4	3	0	16,401	17.2	0	(0.0,8.5)	0.57
Any PNCV	6	16.7	47,516	13.6	1.4	(0.1,10.7)	0.71
H1N1	6	0	57,021	2.8	0	(0.0,49.7)	0.9
HAV	8	25	61,489	13.1	2.4	(0.3,11.9)	0.32
HBV	2	0	2,117	4.5	0	(0.0,53.1)	0.87
Hib	3	0	18,599	13.7	0	(0.0,12.0)	0.65
IIV	22	27.3	294,043	13.6	1.2	(0.3,3.8)	0.79
LAIV	5	20	3,442	15.5	0.6	(0.0,29.0)	0.8
Td	1	0	155	8.4	0	(0.0,207.5)	0.92
Any	47	21.3	823,954	16.2	1.1	(0.5,2.3)	0.79

*This relative risk is estimated by the odds ratio, using the case centered method, as described in Methods.

** Comparison Risk Sets: Cases and Non-cases: All VSD members similar to cases (matched on age, sex, vaccine type and VSD site) on the onset date of the case. N represents the number of people in all the risk sets.

† Vaccine abbreviations are clarified in Table 1 in the publication.

ne: not evaluable; CI: confidence interval